Details for Patent: 8,778,305
✉ Email this page to a colleague
Which drugs does patent 8,778,305 protect, and when does it expire?
Patent 8,778,305 protects PYLARIFY and PYLARIFY TRUVU and is included in two NDAs.
This patent has fifty-five patent family members in twenty-four countries.
Summary for Patent: 8,778,305
| Title: | PSMA-binding agents and uses thereof |
| Abstract: | Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis. |
| Inventor(s): | Martin Pomper, Ronnie Charles Mease, Ying Chen |
| Assignee: | Johns Hopkins University |
| Application Number: | US13/057,044 |
|
Patent Claim Types: see list of patent claims | Use; Device; |
| Patent landscape, scope, and claims: |
More… ↓ |
Drugs Protected by US Patent 8,778,305
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER | ⤷ Start Trial | ||
| Aphelion | PYLARIFY TRUVU | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 220089-001 | Mar 6, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,778,305
| PCT Information | |||
| PCT Filed | July 31, 2009 | PCT Application Number: | PCT/US2009/052456 |
| PCT Publication Date: | February 04, 2010 | PCT Publication Number: | WO2010/014933 |
International Family Members for US Patent 8,778,305
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2318366 | ⤷ Start Trial | 301250 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2318366 | ⤷ Start Trial | CR 2023 00032 | Denmark | ⤷ Start Trial |
| European Patent Office | 2318366 | ⤷ Start Trial | PA2023534 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2318366 | ⤷ Start Trial | 2023C/540 | Belgium | ⤷ Start Trial |
| European Patent Office | 2318366 | ⤷ Start Trial | LUC00323 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 2318366 | ⤷ Start Trial | 37/2023 | Austria | ⤷ Start Trial |
| European Patent Office | 2318366 | ⤷ Start Trial | C20230027 00410 | Estonia | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
